Metronomic Oral Cyclophosphamide in 2 Heavily Pretreated Patients With Metastatic Castration-resistant Prostate Cancer With Homologous Recombination Deficiency (HRD): A Case Report

Clin Genitourin Cancer. 2019 Apr;17(2):157-160. doi: 10.1016/j.clgc.2018.12.005. Epub 2018 Dec 19.

Authors

Hang Huong Ling¹, Yung-Chang Lin²

Affiliations

¹ Division of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital, Keelung Branch, Taiwan.
² Division of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital, Taoyuan Branch, Taiwan; School of Medicine, Chang Gung University, Taoyuan City, Taiwan. Electronic address: yclinof@gmail.com.

PMID: 30630673
DOI: 10.1016/j.clgc.2018.12.005

No abstract available

Keywords: BRCA2; CDK12; DNA alkylating agent; PSA response; mCRPC.

Publication types

Case Reports

MeSH terms

Administration, Metronomic
Aged
Antineoplastic Agents, Alkylating / administration & dosage*
Antineoplastic Agents, Alkylating / therapeutic use
Cyclophosphamide / administration & dosage*
Cyclophosphamide / therapeutic use
Homologous Recombination
Humans
Male
Middle Aged
Mutation
Prostatic Neoplasms, Castration-Resistant / drug therapy*
Prostatic Neoplasms, Castration-Resistant / genetics
Treatment Outcome

Substances

Antineoplastic Agents, Alkylating
Cyclophosphamide